There are now seven FDA-approved GLP-1-based medications on the market, each with its own dosing schedule and use case: Ozempic and Rybelsus (semaglutide) originally approved for type 2 diabetes Wegovy (semaglutide, higher dose) approved specifically for chronic weight management Mounjaro (tirzepatide) a dual GLP-1/GIP agonist approved for diabetes Zepbound (tirzepatide) the weight-loss version of Mounjaro Trulicity and Victoza (dulaglutide and liraglutide) older, well-established options with long safety track records Clinical trial data shows Zepbound and Mounjaro, which act on two different gut hormone receptors instead of one, tend to produce the most dramatic results, with some participants losing between 15% and 22% of their total body weight over the course of a trial
Semaglutide has been available on the NHS since 2019 as a treatment for type 2 diabetes
If transparent pricing is important to you, Nooms advertising will frustrate you
Mounjaro may not be suitable for people with a history of thyroid cancer, pancreatitis, or certain endocrine disorders
The procerus (top of the nose) pulls the forehead skin down
KosiborodMNAbildstrmSZBorlaugBAButlerJChristensenLDaviesMet alDesign and baseline characteristics of STEP-HFpEF program evaluating semaglutide in patients with obesity HFpEF phenotype
